-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SpringWorks Therapeutics (NASDAQ:SWTX) PT Raised to $103.00 at HC Wainwright
SpringWorks Therapeutics (NASDAQ:SWTX) PT Raised to $103.00 at HC Wainwright
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) had its price target hoisted by HC Wainwright from $94.00 to $103.00 in a report published on Monday morning, The Fly reports. They currently have a buy rating on the stock.
Other equities analysts have also issued reports about the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research note on Monday, June 20th. The Goldman Sachs Group dropped their target price on SpringWorks Therapeutics from $92.00 to $76.00 and set a buy rating for the company in a research note on Tuesday, May 24th.
Get SpringWorks Therapeutics alerts:SpringWorks Therapeutics Stock Up 12.8 %
NASDAQ SWTX opened at $31.98 on Monday. SpringWorks Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $77.70. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -6.86 and a beta of 0.85. The business has a fifty day moving average of $28.97 and a 200-day moving average of $37.75.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). SpringWorks Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.97) earnings per share. As a group, analysts anticipate that SpringWorks Therapeutics will post -5.46 EPS for the current year.Institutional Investors Weigh In On SpringWorks Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Amundi purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $77,000. Legal & General Group Plc grew its position in SpringWorks Therapeutics by 30.6% during the second quarter. Legal & General Group Plc now owns 28,429 shares of the company's stock valued at $700,000 after acquiring an additional 6,660 shares during the period. ExodusPoint Capital Management LP purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $663,000. Walleye Capital LLC purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $1,624,000. Finally, Goldman Sachs Group Inc. grew its position in SpringWorks Therapeutics by 21.5% during the second quarter. Goldman Sachs Group Inc. now owns 270,687 shares of the company's stock valued at $6,665,000 after acquiring an additional 47,978 shares during the period.
About SpringWorks Therapeutics
(Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) had its price target hoisted by HC Wainwright from $94.00 to $103.00 in a report published on Monday morning, The Fly reports. They currently have a buy rating on the stock.
据The Fly报道,在周一上午发布的一份报告中,HC Wainwright将SpringWorks Treateutics(纳斯达克:SWTX-GET评级)的目标价从94美元上调至103.00美元。他们目前对该股的评级为买入。
Other equities analysts have also issued reports about the company. Wedbush set a $53.00 target price on SpringWorks Therapeutics in a research note on Monday, June 20th. The Goldman Sachs Group dropped their target price on SpringWorks Therapeutics from $92.00 to $76.00 and set a buy rating for the company in a research note on Tuesday, May 24th.
其他股票分析师也发布了有关该公司的报告。韦德布什在6月20日星期一的一份研究报告中为SpringWorks治疗公司设定了53.00美元的目标价格。5月24日,高盛夫妇在一份周二的研究报告中将SpringWorks Treateutics的目标价从92.00美元下调至76.00美元,并为该公司设定了买入评级。
SpringWorks Therapeutics Stock Up 12.8 %
SpringWorks治疗公司股票上涨12.8%
NASDAQ SWTX opened at $31.98 on Monday. SpringWorks Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $77.70. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -6.86 and a beta of 0.85. The business has a fifty day moving average of $28.97 and a 200-day moving average of $37.75.
纳斯达克SWTX周一开盘报31.98美元。SpringWorks Treateutics的股价为52周低点13.60美元,52周高点为77.70美元。该股市值15.8亿美元,市盈率为-6.86倍,贝塔系数为0.85。该业务的50日移动均线切入位为28.97美元,200日移动均线切入位为37.75美元。
Institutional Investors Weigh In On SpringWorks Therapeutics
机构投资者看好SpringWorks治疗公司
A number of institutional investors have recently added to or reduced their stakes in the company. Amundi purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $77,000. Legal & General Group Plc grew its position in SpringWorks Therapeutics by 30.6% during the second quarter. Legal & General Group Plc now owns 28,429 shares of the company's stock valued at $700,000 after acquiring an additional 6,660 shares during the period. ExodusPoint Capital Management LP purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $663,000. Walleye Capital LLC purchased a new stake in SpringWorks Therapeutics during the second quarter valued at about $1,624,000. Finally, Goldman Sachs Group Inc. grew its position in SpringWorks Therapeutics by 21.5% during the second quarter. Goldman Sachs Group Inc. now owns 270,687 shares of the company's stock valued at $6,665,000 after acquiring an additional 47,978 shares during the period.
一些机构投资者最近增持或减持了该公司的股份。Amundi在第二季度购买了SpringWorks治疗公司的新股份,价值约7.7万美元。Legal&General Group Plc在第二季度将其在SpringWorks Treateutics的地位增加了30.6%。Legal&General Group Plc在此期间又收购了6660股,现在拥有28,429股该公司股票,价值70万美元。ExodusPoint Capital Management LP在第二季度购买了SpringWorks Treateutics的新股份,价值约66.3万美元。Walleye Capital LLC在第二季度购买了SpringWorks Treateutics的新股份,价值约1,624,000美元。最后,高盛公司在第二季度将其在SpringWorks治疗公司的头寸增加了21.5%。高盛股份有限公司在此期间增持了47,978股,目前持有270,687股公司股票,价值6,665,000美元。
About SpringWorks Therapeutics
关于SpringWorks治疗公司
(Get Rating)
(获取评级)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
SpringWorks治疗公司为患有罕见疾病和癌症的未得到充分服务的患者群体收购、开发和商业化药物。它的主要候选产品是Niroacestat,一种口服小分子伽马分泌酶抑制剂,正在进行治疗韧带样肿瘤的第三阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免费获取StockNews.com关于SpringWorks治疗公司(SWTX)的研究报告
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得SpringWorks治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SpringWorks Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧